Danaher Corporation
0R2B.L
London Stock Exchange177.25
USD
-1.13
- -
Danaher Corporation
0R2B.L
(London Stock Exchange)
Recent
price
177.25
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Danaher Corporation operates as a global science and technology innovator specializing in healthcare and environmental solutions. The company’s core products and services are organized through four main segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions. The Life Sciences segment offers laboratory instruments and consumables, analytical tools, digital solutions, and products for drug research, therapeutic development, and biopharmaceutical manufacturing. The Diagnostics segment develops instruments, consumables, software, and services for disease diagnosis and clinical testing. The Dental segment provides dental equipment and consumables, while the Environmental & Applied Solutions segment offers products and services related to water quality, product identification, and environmental testing. Danaher serves customers globally, including clinical research facilities, pharmaceutical companies, healthcare providers, and industrial clients. Founded in 1969, Danaher is headquartered in Washington, D.C. Recent major company developments include a strategic partnership with AstraZeneca to scale precision medicine initiatives, focusing on the development and commercialization of next-generation AI-powered diagnostics. Danaher has also formed an investment partnership with Innovaccer Inc., aimed at accelerating the transition to precision medicine using AI-enabled diagnostic tools that improve patient outcomes. Additionally, the company announced new leadership appointments emphasizing technological innovation and AI integration. Danaher continues to expand its innovation ecosystem through partnerships and investments that leverage its subsidiaries, including Leica Biosystems, Cytiva, Aldevron, and Beckman Coulter Diagnostics, enhancing its capabilities in diagnostics and life sciences innovation. The corporation maintains a steady financial performance while advancing its portfolio in biotechnology, diagnostics, and life sciences markets across North America, Europe, and Asia.